Drug Search Results
More Filters [+]

Ruzasvir

Alternative Names: ruzasvir, mk-8408, mk 8408, mk8408
Latest Update: 2024-12-18
Latest Update Note: News Article

Product Description

Mechanisms of Action: HCV-NS5A Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Merck
Company Location: KENILWORTH NJ 07033
Company CEO: Robert M. Davis
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Ruzasvir

Countries in Clinic: Brazil, Canada, India, Korea, Mauritius, Moldova, Pakistan, Philippines, Romania, South Africa, Turkey, United States

Active Clinical Trial Count: 4

Highest Development Phases

Phase 2: Hepatitis A|Hepatitis C, Chronic|Liver Cirrhosis

Phase 1: Healthy Volunteers

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

2023-000160-54

P2

Active, not recruiting

Hepatitis C, Chronic

2025-02-17

AT-01B-004

P2

Active, not recruiting

Liver Cirrhosis|Hepatitis A|Hepatitis C, Chronic

2024-11-01

AT-01B-005

P1

Completed

Healthy Volunteers

2024-08-25

AT-01B-006

P1

Completed

Healthy Volunteers

2024-05-30

Recent News Events